Cloning techniques to identify genes and peptides of tumor-associated antigens have
created new possibilities for the immunotherapy of patients with advanced cancer. Here, we …

In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination
strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP …

The first generation of human cancer vaccines has been tested in phase III clinical trials, but
only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This …

Most of gastrointestinal, breast and lung cancer cells express carcinoembryonic antigen
(CEA). Therefore, this protein represents a suitable target for innovative diagnostic and …

Cancer vaccines have emerged as powerful and clinically viable therapeutic modalities to
reduce tumor burden, eradicate residual cancer cells and prevent relapse. The past years …

Abstract The MC-38 C57BL/6 mouse colon adenocarcinoma cell line has been transduced
with a retroviral construct containing cDNA encoding the human carcinoembryonic antigen …

Background CEA is expressed in> 90% of pancreatic cancers (PC) and may be an
appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; …

Cancer vaccines are entering a new phase of popularity, in part because of the recognition
of when a therapeutic vaccine is most effective and the identification of appropriate target …

Abstract Yeast-CEA (GI-6207) is a therapeutic cancer vaccine genetically modified to
express recombinant carcinoembryonic antigen (CEA) protein, using heat-killed yeast …

Cancer vaccines–a dream or a reality? There is no doubt that a time will come when this
new approach to cancer treatment will provide opportunities that will be both complementary …